Loading...
XSHE002038
Market cap1.02bUSD
Jan 22, Last price  
7.27CNY
1D
0.55%
1Q
-4.72%
Jan 2017
-59.18%
Name

Beijing SL Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
17.82
P/S
7.29
EPS
0.41
Div Yield, %
2.06%
Shrs. gr., 5y
8.21%
Rev. gr., 5y
-14.02%
Revenues
1.02b
-3.03%
93,051,498118,557,674143,936,377237,530,969358,002,928390,024,556457,842,025622,772,1651,007,017,7821,161,778,7481,242,951,5241,156,548,1511,009,847,4131,242,076,2692,167,471,6682,029,703,6591,112,733,8021,214,810,5241,050,165,4261,018,358,696
Net income
417m
+77.77%
32,002,22633,821,40050,321,043134,800,571217,858,676244,104,839272,714,180523,344,976481,011,146577,397,433695,083,054575,049,108452,107,589533,575,372571,449,518486,783,623364,708,684425,939,565234,404,162416,691,942
CFO
460m
+18.05%
31,262,28647,481,05657,552,51188,363,104194,321,168174,405,160238,134,139228,591,711398,595,751347,413,924465,004,184504,870,454396,861,456380,724,354485,173,510665,826,611415,837,437464,629,521389,820,900460,197,296
Dividend
Jul 04, 20240.15 CNY/sh

Profile

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.
IPO date
Sep 09, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,018,359
-3.03%
1,050,165
-13.55%
Cost of revenue
641,496
768,904
Unusual Expense (Income)
NOPBT
376,862
281,261
NOPBT Margin
37.01%
26.78%
Operating Taxes
49,937
31,010
Tax Rate
13.25%
11.03%
NOPAT
326,925
250,252
Net income
416,692
77.77%
234,404
-44.97%
Dividends
(102,735)
(102,735)
Dividend yield
0.99%
1.22%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
(27,873)
Long-term debt
Deferred revenue
47,041
51,379
Other long-term liabilities
Net debt
(3,665,509)
(2,062,966)
Cash flow
Cash from operating activities
460,197
389,821
CAPEX
(218,360)
Cash from investing activities
(378,027)
Cash from financing activities
(102,735)
(102,735)
FCF
996,236
368,752
Balance
Cash
2,078,251
739,944
Long term investments
1,587,258
1,295,149
Excess cash
3,614,591
1,982,585
Stockholders' equity
5,809,607
5,478,808
Invested Capital
2,349,766
3,511,177
ROIC
11.16%
7.46%
ROCE
6.27%
5.07%
EV
Common stock shares outstanding
1,016,322
1,027,350
Price
10.19
23.97%
8.22
-23.96%
Market cap
10,356,319
22.64%
8,444,817
-23.96%
EV
6,700,232
6,393,007
EBITDA
522,537
395,140
EV/EBITDA
12.82
16.18
Interest
66
103
Interest/NOPBT
0.02%
0.04%